Abstract: Objective To explore the efficacy and safety of combination of oxaliplatin and capecitabine (XELOX) plus bevacizumab in conversion treatment of patients with colon cancer and liver metastasis. Methods A total of 41 patients with de novo unresectable colon cancer and liver metastases were enrolled in our hospital between June 2015 and July 2017, and all patients underwent XELOX and bevacizumab for conversion therapy. The response rate, conversion surgical rate and overall survival time (OS) were observed. Results All patients finished at least four courses of conversion therapy, and 31 patients (75.6%) had partial response, 14 patients (34.1%) underwent radical surgery after conversion treatment; 40 patients were followed up for 13 to 26 months with the medium of 18 months and one patient after radical surgery lost, and one-year survival at radical surgery and non-surgery group were 92.3% and 66.7%, which showed significantly difference by Log-rank testing (P=0.019).Conclusion The administration of bevacizumab plus XELOX regimen is safe and efficacious in the conversion treatment of patients with colon cancer and simultaneous liver metastases, and parts of patients might obtain opportunity for radical surgery, which is expected to prolong the survival time.

Key words: Liver metastases, Colon cancer, Bevacizumab, Conversion therapy, Survival